GENETIC POLYMORPHISMS ASSOCIATED WITH CLINICAL OUTCOMES OF TOPOISOMERASE INHIBITOR THERAPY FOR CANCER

摘要

The invention provides compositions and methods for determining the likelihood of response or survival of cancer patients treated with topoisomerase inhibitor therapy or anti-EGFR and topoisomerase inhibitor therapy combination therapy. After determining if a patient is likely to be successfully treated, the invention also provides methods for treating the patients.